Bora Biologics Partners with DotBio on Groundbreaking Antibody Therapy

Bora Biologics, a rapidly expanding division of Bora Pharmaceuticals, has announced a strategic partnership with DotBio, a Singapore-based biopharmaceutical company specializing in cutting-edge antibody therapies. The collaboration focuses on the development and manufacturing of DotBio’s leading tri-specific antibody candidate, DB007, designed to target specific, undisclosed cancer markers.

Supporting Innovation in Cancer Treatment

DotBio’s novel tri-specific antibody holds promise as a groundbreaking cancer therapy. Bora Biologics will provide comprehensive development and manufacturing support, including chemistry, manufacturing, and controls (CMC) strategy, from its advanced center of excellence in Zhubei, Taiwan. Spanning 48,400 square feet, the facility is equipped to handle complex biologics and offers state-of-the-art capabilities to streamline early clinical development.

Leadership Perspectives on the Collaboration

“Bora Biologics delivers tailored development and manufacturing plans that provide full-spectrum support for our clients,” said Bobby Sheng, Chairman and CEO of Bora Group. “With our Zhubei operations fully operational, we are well-prepared to offer high-yield manufacturing processes and sophisticated program management to tackle even the most challenging molecules.”

DotBio CEO and Founder Ignacio Asial, Ph.D., expressed confidence in the partnership:
“We selected Bora Biologics because of their exceptional expertise in early-phase biologics development and their proven ability to manufacture multi-specific antibodies efficiently. Bora’s facilities in Taiwan align perfectly with our IND-development phase, while their commercial-scale manufacturing facilities in the U.S. will ensure we can expand globally to treat patients. It’s exciting to collaborate with one of the top CDMO partners in Asia to bring our innovative therapy to life.”

Capabilities at Bora Biologics’ Zhubei Facility

Bora’s Zhubei facility is uniquely equipped to support early-stage biologics development, offering services such as:

• Lead candidate screening
• In vitro and biochemical/physical assays
• Complex protein preparation and purification
• Production of monoclonal, bispecific, and multi-specific antibodies, as well as other recombinant proteins for research and development

Advancing Cancer Care Together

This partnership marks a significant step forward in the development of DB007 and highlights the growing role of innovative biologics in oncology. By combining Bora Biologics’ end-to-end manufacturing expertise with DotBio’s cutting-edge science, the collaboration sets the stage for accelerated progress toward global cancer treatment solutions.